Eli Lilly Has Momentum But Valuation Raises Questions
Eli Lilly (LLY) has experienced a 53% stock price increase over the past twelve months, driven by exceptional business performance from its diabetes and obesity drug franchise. The company's revenue grew 47% in the last year, far exceeding the S&P 500 median, and its operating margin stands at 47%. However, the stock trades at a high price-to-earnings multiple of 41.6, significantly above the market median of 24.3. Management has raised full-year 2026 revenue guidance to $82-85 billion, but faces pricing headwinds in the low to mid-teens. The article questions whether the current stock price already accounts for future success, and notes that the company's ability to meet its updated guidance is the key watchable for the remainder of the year. The piece also discusses portfolio concentration risks given LLY's 417% gain over five years.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection